Drug utilization review of risperidone for outpatients in a tertiary referral hospital in Singapore

Luo, Nan; Koh, Yvonne; Tan, Chay Hoon; Kua, Ee Heok; Li, Shu Chuen

doi:10.1002/hup.585

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SGAs are generally considered to have lower risk of EPS than FGAs; however, in the case of risperidone, both Luo et al 32 and our study did not find a lower EPS risk. Furthermore, we found that not all SGAs have a similar risk.…”

Section: Discussioncontrasting

confidence: 85%

Risk of Extrapyramidal Syndrome in Schizophrenic Patients Treated with Antipsychotics: A Population-based Study

Yang

Chong

et al. 2007

Clin Pharmacol Ther

View full text Add to dashboard Cite

To compare the prevalence of extrapyramidal syndrome (EPS) between the first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs), the co-prescribing rate of anti-Parkinson drugs (APDs) of each antipsychotic drug was analyzed using population database. Fourteen antipsychotics had been prescribed during the 5-year study period. Among the SGAs, quetiapine had the lowest crude co-prescribing rate of APDs (27.09%), whereas risperidone had the highest rate (66.50%). Among the FGAs, thioridazine and loxapine had the lowest (60.99%) and highest rates (96.35%), respectively. The rankings of the co-prescribing rate of APDs among antipsychotics, in increasing order, were quetiapine, clozapine, olanzapine, thioridazine, zotepine, chlorpromazine, risperidone, sulpiride, clotiapine, flupentixol, haloperidol, zuclopentixol, trifluoperazine, and loxapine. The results indicate that the risk of EPS appears to be lower in SGAs than in FGAs; however, the considerably high rate of EPS in some of the newer generation of antipsychotics warrants clinical attention.

show abstract

Section: Discussioncontrasting

confidence: 85%